The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing

John B Christoforidis, Jillian Wang, Angela Jiang, James Willard, Cedric Pratt, Mahmoud Abdel-Rasoul, Sashwati Roy, Heather Powell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following intravitreal injection. Methods: A total of 120 New Zealand white rabbits were randomly assigned to one of three treatment groups each consisting of 40 rabbits. Each group received intravitreal injections of bevacizumab, ranibizumab, or normal saline. Immediately afterwards, each rabbit underwent four 6 mm full-thickness dermatologic punch biopsies. Twenty rabbits from each agent group underwent wound harvesting on day 7 or day 14. The skin samples were stained for CD34 for vascular endothelial cells on day 7, and maximal wound tensile load was measured on days 7 and 14. Quantitative assessment of mean neovascularization (MNV) scores was obtained from 10 contiguous biopsy margin 400× fields of CD34-stained sections by two independent observers. Results: Wound tension reading means (N) with standard error and adjusted P-values on day 7 were: saline placebos, 7.46 ± 0.87; bevacizumab, 4.50 ± 0.88 (P = 0.041); and ranibizumab, 4.67 ± 0.84 (P = 0.025). On day 14 these were: saline placebos, 7.34 ± 0.55; bevacizumab, 6.05 ± 0.54 (P = 0.18); and ranibizumab 7.99 ± 0.54 (P = 0.40). MNV scores in CD34 stained sections were: saline controls, 18.31 ± 0.43; bevacizumab, 11.02 ± 0.45 (P<0.0001); and ranibizumab, 13.55 ± 0.43 (P<0.0001). The interobserver correlation coefficient was 0.928. Conclusion: At day 7, both anti-vascular endothelial growth factor (anti-VEGF) agents had significantly suppressed MNV scores and exerted a significant reduction of cutaneous wound tensile strength compared with saline controls. At day 14, neither agent produced a significant effect on tensile wound strength. Since angiogenesis is an integral component of the proliferative phase of wound healing, we encourage clinicians to be aware of their patients' recent surgical history during intravitreal anti-VEGF therapy and to consider refraining from their use during the perioperative period.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalClinical Ophthalmology
Volume7
DOIs
StatePublished - Jan 23 2013

Fingerprint

Tensile Strength
Wound Healing
Skin
Rabbits
Wounds and Injuries
Intravitreal Injections
Vascular Endothelial Growth Factor A
Placebos
Biopsy
Placebo Effect
Perioperative Period
Ranibizumab
Bevacizumab
Reading
Endothelial Cells
History
Therapeutics

Keywords

  • Bevacizumab
  • Ranibizumab
  • Tensile strength
  • Wound healing

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. / Christoforidis, John B; Wang, Jillian; Jiang, Angela; Willard, James; Pratt, Cedric; Abdel-Rasoul, Mahmoud; Roy, Sashwati; Powell, Heather.

In: Clinical Ophthalmology, Vol. 7, 23.01.2013, p. 185-191.

Research output: Contribution to journalArticle

Christoforidis, John B ; Wang, Jillian ; Jiang, Angela ; Willard, James ; Pratt, Cedric ; Abdel-Rasoul, Mahmoud ; Roy, Sashwati ; Powell, Heather. / The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. In: Clinical Ophthalmology. 2013 ; Vol. 7. pp. 185-191.
@article{2fc8193f254d464da4818f4747fa168a,
title = "The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing",
abstract = "Purpose: To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following intravitreal injection. Methods: A total of 120 New Zealand white rabbits were randomly assigned to one of three treatment groups each consisting of 40 rabbits. Each group received intravitreal injections of bevacizumab, ranibizumab, or normal saline. Immediately afterwards, each rabbit underwent four 6 mm full-thickness dermatologic punch biopsies. Twenty rabbits from each agent group underwent wound harvesting on day 7 or day 14. The skin samples were stained for CD34 for vascular endothelial cells on day 7, and maximal wound tensile load was measured on days 7 and 14. Quantitative assessment of mean neovascularization (MNV) scores was obtained from 10 contiguous biopsy margin 400× fields of CD34-stained sections by two independent observers. Results: Wound tension reading means (N) with standard error and adjusted P-values on day 7 were: saline placebos, 7.46 ± 0.87; bevacizumab, 4.50 ± 0.88 (P = 0.041); and ranibizumab, 4.67 ± 0.84 (P = 0.025). On day 14 these were: saline placebos, 7.34 ± 0.55; bevacizumab, 6.05 ± 0.54 (P = 0.18); and ranibizumab 7.99 ± 0.54 (P = 0.40). MNV scores in CD34 stained sections were: saline controls, 18.31 ± 0.43; bevacizumab, 11.02 ± 0.45 (P<0.0001); and ranibizumab, 13.55 ± 0.43 (P<0.0001). The interobserver correlation coefficient was 0.928. Conclusion: At day 7, both anti-vascular endothelial growth factor (anti-VEGF) agents had significantly suppressed MNV scores and exerted a significant reduction of cutaneous wound tensile strength compared with saline controls. At day 14, neither agent produced a significant effect on tensile wound strength. Since angiogenesis is an integral component of the proliferative phase of wound healing, we encourage clinicians to be aware of their patients' recent surgical history during intravitreal anti-VEGF therapy and to consider refraining from their use during the perioperative period.",
keywords = "Bevacizumab, Ranibizumab, Tensile strength, Wound healing",
author = "Christoforidis, {John B} and Jillian Wang and Angela Jiang and James Willard and Cedric Pratt and Mahmoud Abdel-Rasoul and Sashwati Roy and Heather Powell",
year = "2013",
month = "1",
day = "23",
doi = "10.2147/OPTH.S40537",
language = "English (US)",
volume = "7",
pages = "185--191",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing

AU - Christoforidis, John B

AU - Wang, Jillian

AU - Jiang, Angela

AU - Willard, James

AU - Pratt, Cedric

AU - Abdel-Rasoul, Mahmoud

AU - Roy, Sashwati

AU - Powell, Heather

PY - 2013/1/23

Y1 - 2013/1/23

N2 - Purpose: To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following intravitreal injection. Methods: A total of 120 New Zealand white rabbits were randomly assigned to one of three treatment groups each consisting of 40 rabbits. Each group received intravitreal injections of bevacizumab, ranibizumab, or normal saline. Immediately afterwards, each rabbit underwent four 6 mm full-thickness dermatologic punch biopsies. Twenty rabbits from each agent group underwent wound harvesting on day 7 or day 14. The skin samples were stained for CD34 for vascular endothelial cells on day 7, and maximal wound tensile load was measured on days 7 and 14. Quantitative assessment of mean neovascularization (MNV) scores was obtained from 10 contiguous biopsy margin 400× fields of CD34-stained sections by two independent observers. Results: Wound tension reading means (N) with standard error and adjusted P-values on day 7 were: saline placebos, 7.46 ± 0.87; bevacizumab, 4.50 ± 0.88 (P = 0.041); and ranibizumab, 4.67 ± 0.84 (P = 0.025). On day 14 these were: saline placebos, 7.34 ± 0.55; bevacizumab, 6.05 ± 0.54 (P = 0.18); and ranibizumab 7.99 ± 0.54 (P = 0.40). MNV scores in CD34 stained sections were: saline controls, 18.31 ± 0.43; bevacizumab, 11.02 ± 0.45 (P<0.0001); and ranibizumab, 13.55 ± 0.43 (P<0.0001). The interobserver correlation coefficient was 0.928. Conclusion: At day 7, both anti-vascular endothelial growth factor (anti-VEGF) agents had significantly suppressed MNV scores and exerted a significant reduction of cutaneous wound tensile strength compared with saline controls. At day 14, neither agent produced a significant effect on tensile wound strength. Since angiogenesis is an integral component of the proliferative phase of wound healing, we encourage clinicians to be aware of their patients' recent surgical history during intravitreal anti-VEGF therapy and to consider refraining from their use during the perioperative period.

AB - Purpose: To investigate the effect of intravitreal bevacizumab and ranibizumab on wound tension and by histopathology during cutaneous wound healing in a rabbit model and to compare this effect to placebo intravitreal saline controls 1 and 2 weeks following intravitreal injection. Methods: A total of 120 New Zealand white rabbits were randomly assigned to one of three treatment groups each consisting of 40 rabbits. Each group received intravitreal injections of bevacizumab, ranibizumab, or normal saline. Immediately afterwards, each rabbit underwent four 6 mm full-thickness dermatologic punch biopsies. Twenty rabbits from each agent group underwent wound harvesting on day 7 or day 14. The skin samples were stained for CD34 for vascular endothelial cells on day 7, and maximal wound tensile load was measured on days 7 and 14. Quantitative assessment of mean neovascularization (MNV) scores was obtained from 10 contiguous biopsy margin 400× fields of CD34-stained sections by two independent observers. Results: Wound tension reading means (N) with standard error and adjusted P-values on day 7 were: saline placebos, 7.46 ± 0.87; bevacizumab, 4.50 ± 0.88 (P = 0.041); and ranibizumab, 4.67 ± 0.84 (P = 0.025). On day 14 these were: saline placebos, 7.34 ± 0.55; bevacizumab, 6.05 ± 0.54 (P = 0.18); and ranibizumab 7.99 ± 0.54 (P = 0.40). MNV scores in CD34 stained sections were: saline controls, 18.31 ± 0.43; bevacizumab, 11.02 ± 0.45 (P<0.0001); and ranibizumab, 13.55 ± 0.43 (P<0.0001). The interobserver correlation coefficient was 0.928. Conclusion: At day 7, both anti-vascular endothelial growth factor (anti-VEGF) agents had significantly suppressed MNV scores and exerted a significant reduction of cutaneous wound tensile strength compared with saline controls. At day 14, neither agent produced a significant effect on tensile wound strength. Since angiogenesis is an integral component of the proliferative phase of wound healing, we encourage clinicians to be aware of their patients' recent surgical history during intravitreal anti-VEGF therapy and to consider refraining from their use during the perioperative period.

KW - Bevacizumab

KW - Ranibizumab

KW - Tensile strength

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84873161175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873161175&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S40537

DO - 10.2147/OPTH.S40537

M3 - Article

C2 - 23378736

AN - SCOPUS:84873161175

VL - 7

SP - 185

EP - 191

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -